product summary
company name :
Badrilla
product type :
antibody
product name :
CaMK II Phospho Threonine-286 Anti-Serum
catalog :
A010-50
quantity :
20 ul
price :
GBP184.46
clonality :
polyclonal
host :
rabbit
conjugate :
nonconjugated
antigen modification :
phosphorylated
reactivity :
human, mouse, cow, zebrafish
application :
western blot
more info or order :
Badrilla product webpage
citations: 1
Published Application/Species/Sample/DilutionReference
  • western blot; mouse; fig 2a
Xie L, Pi X, Townley-Tilson W, Li N, Wehrens X, Entman M, et al. PHD2/3-dependent hydroxylation tunes cardiac response to β-adrenergic stress via phospholamban. J Clin Invest. 2015;125:2759-71 pubmed publisher
product information
Catalog Number :
A010-50
Product Name :
CaMK II Phospho Threonine-286 Anti-Serum
Host Species :
Rabbit
Clonality :
polyclonal
Antigen Modification :
Phospho-Threonine
Product Type :
Polyclonal Ab
Size :
20 ul
List Price :
GBP184.46
Gene ID :
816
Product Description :
Polyclonal antibody specific to alpha isoform of CaMKII Phospho Thr-286 (or Thr287 in beta delta, gamma isoforms of CaMKII) (CaMKII site).
CrossReactivity :
The antibody recognises both of the alpha and beta subunits of CaMKII when phosphorylated at Thr-286. Binding of the antibody to its target epitope is blocked in the presence of a phosphopeptide containing the CaMKII Phospho Thr-286 epitope.
SpeciesSummary :
Reacts with rat. Not yet tested in other species. However, from primary sequence analysis, the antibody will recognise Phospho Thr-286 (or 287) in all isoforms (alpha, beta, gamma and delta) from human, rat and mouse. The antibody is also expected to react with various isoforms from chicken, cow, pig, rabbit, zebrafish, and Xenopus laevis
Background :
Ca2+/calmodulin-dependent kinase II (CaMKII) is a ubiquitous, multifunctional serine/threonine kinase involved in translating Ca2+- transient signals into cellular responses. Four separate CaMKII genes are expressed in man (alpha, beta, delta, gamma) with isoforms within each gene. CaMKII delta and gamma are abundant in the heart. CaMKII is activated by Ca2+/CaM binding, and becomes activated for prolonged periods of time following autophosphorylation of Thr-286 or Thr-287 (equivalent residues in different isoforms). This antibody recognizes the active, autophosphorylated enzyme (all isoforms) and thus can measure the abundance of active CaMKII. Prolonged activation of CaMKII is associated with a variety of vascular and cardiac diseases including stroke, atrial fibrillation cardiac arrhythmia & sudden death, cardiac apoptosis, and heart failure.
Immunogen :
Synthetic peptide (M281HRQET(PO3H2)VDC289) corresponding to amino acids surrounding the phosphorylated threonine residue at position 286 (or 287) of CaMKII, which was conjugated to keyhole limpet hemocyanin (KLH) by carbodiimide cross linkage
Specificity :
The antibody recognises both of the alpha and beta subunits of CaMKII when phosphorylated at Thr-286. Binding of the antibody to its target epitope is blocked in the presence of a phosphopeptide containing the CaMKII Phospho Thr-286 epitope.
Purity :
Raw Serum
Preservative :
Lyophilised:
Packaging :
0.5 ml Cryovial
Uses :
WB 1:5000
Application Summary :
WB (1:5000)
Storage :
Lyophilised antibody is stable at 4 °C when stored with desiccant. Reconstitute lyophilised powder in 20 ul of 18 MΩ H2O, aliquot and store frozen at -80 °C for 1 year. Avoid freese - thaw cycles
Product References :
Shulman, H. & Braun, A.P. (1999) in Carafoli E. & Klee, C. (Eds.) Calcium as a Cellular Regulator, Oxford University Press
more info or order :
Badrilla product webpage
company information
Badrilla
Leeds Innovation Centre
103 Clarendon Road
Leeds, LS2 9DF
info@badrilla.com
www.badrilla.com
011334 31869
headquarters: UK
Badrilla Ltd. is a biotechnology company founded in 2003 and located in Leeds, UK. Badrilla makes and distributes exceptional monoclonal and polyclonal antibodies to cardiovascular protein and phospho-protein targets. We source excellent antibodies from academic leaders and re-validate antibodies not made by ourselves in assays of relevance to our customers. Working with outstanding academic collaborators, we are developing new technologies to calibrate immunoassays, which will enable the performance of genuinely Quantitative Western blotting, Quantitative biomarker measurement, and Quantitative diagnostics. Our aim is to provide products that work first time in the applications you deploy, which accelerate the progress of your research, and which satisfy your expectations in every way.